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ABSTRACT: At the 2019 annual meeting of the Group for Research and 
Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members received 
updates on several ongoing efforts. Among them were updates on research, 
including the trainee symposium, pilot research grants, and Collaborative Research 
Network; GRAPPA’s patient research partners; education, including the slide 
collection; treatment recommendations; and additional undertakings related to 
advancing the understanding of disease aspects, including the Outcome Measures 
in Rheumatology (OMERACT)-GRAPPA outcome measure, axial, ultrasound 
enthesitis projects, as well as the early psoriatic disease systematic literature review 
and magnetic resonance imaging.  
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Members of the Group for Research and Assessment of Psoriasis and Psoriatic 
Arthritis (GRAPPA) continue to pursue the core objectives of GRAPPA’s mission, 
specifically, to provide education, identify research assessment tools, and pursue 
research in disease pathophysiology. At the 2019 annual GRAPPA meeting in Paris, 
France, members received updates on research, including the trainee symposium, 
pilot research grants, and Collaborative Research Network (CRN); GRAPPA’s 
patient research partners (PRPs); education, including the slide collection; treatment 
recommendations; and additional undertakings related to advancing the 
understanding of disease aspects, including the Outcome Measures in 
Rheumatology (OMERACT)-GRAPPA outcome measure, axial, and ultrasound 
enthesitis projects, as well as the early psoriatic arthritis (PsA) systematic literature 
review and magnetic resonance imaging (MRI). 
Research Committee 
Dr. Oliver FitzGerald reported that the GRAPPA CRN held a very productive pre-
meeting. The pre-meeting was held to review progress on the development of an 
electronic case report form (eCRF), standardized operating procedures (SOPs), and 
shared database to be used in CRN studies; to obtain feedback on the SOPs 
needed for sample collection; and to propose an investigator-initiated study that 
would allow for testing of both the eCRF and SOPs. The appointment of a 
coordinator for the CRN was announced with the remit of the coordinator being to 
develop the eCRF and SOPs. As a result of the meeting, the CRN committee 
planned to proceed with a more detailed treatment response study design to guide 
the development of the eCRF and SOPs.  
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Continued progress on the PsA Biomarkers of Joint DAMage (BioDAM) 
project was reported, especially with relation to obtaining samples from various 
industry-sponsored trials in PsA. This included a signed contract with Lilly, with 
shipping of samples from the ixekizumab PsA program planned in fall 2019; a 
contract under discussion with Amgen to access samples from the SEAM study; and 
a contract under discussion with Pfizer related to the tofacitinib program to predict 
treatment response.  
GRAPPA is now registered in the European Union (EU) in The Netherlands to 
allow GRAPPA to participate in EU-funded research programs. As part of this effort, 
GRAPPA continues to pursue a psoriatic disease-specific call for research in areas 
of major unmet need with the EU-based Innovative Medicines Initiative (IMI). While 
the call for proposals was issued in late 2018, it will likely not proceed until early 
2020. Meanwhile, contact was made with the United States (US) National Institutes 
of Health (NIH) regarding the possibility of an Accelerated Medicines Partnership 
(AMP)-type program in psoriatic disease.  
Dr. Christopher Ritchlin reported that there were 26 applications for the pilot 
research grants compared to 22 in 2018. Once again, 3 were awarded at $25,000 
each to Maria Angioni (Italy) for her study evaluating the pharmacogenetics of 
treatment response in PsA; Alla Ishchenko (Belgium) on metabolomic profiling in 
psoriatic disease; and Zhenrui Shi (USA) on the preclinical analysis of CCR6 and 
CCL20 in mouse and human joints. The Research Committee will send a new 
request for applications in early 2020 with additional information and details provided 
at that time.  
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Additionally, results to date from the 3 research projects awarded in 2018 
were presented. Dr. Fardina Malik (USA) presented on the effect of medium-chain 
fatty acid (MCFA) supplementation on PsA and psoriasis. She noted that 39% of 
psoriatic disease patients report the use of complementary and alternative medicine. 
She explored how MCFA supplementation, specifically pure extra virgin coconut oil 
(PEVCO), regulates psoriatic disease. Theoretically, MCFA in immune regulation 
could alter gut microbiota, have an antimicrobial effect, modulate T cell function, 
increase interleukin (IL)-10 levels, and decrease levels of tumor necrosis factor alpha 
(TNFα). In the study, patients with active psoriasis with or without PsA began 
PEVCO supplementation for 6 weeks. They underwent assessment of their skin, 
joints, and microbiome, and they completed the Multi-dimensional Health 
Assessment Questionnaire. So far, 14 individuals have been recruited with a median 
age of 42.5 years (57% female). While no changes in clinical disease activity were 
seen, after 3 weeks of MCFA supplementation, a change in the levels of firmicutes 
and clostridia was seen in the gut microbiome as well as decreases in the level of IL-
22.  
Kim Wervers and Dr. Hannah den Braanker (The Netherlands) presented on 
the response to methotrexate (MTX) and a quest for personalized medicine in PsA. 
Their objectives were to determine how often a good response to MTX occurs in 
daily practice in early PsA patients and what differences exist between responders 
versus non-responders. They evaluated 219 PsA patients with 1 year or less of 
oligo/polyarthritis of whom 183 (84%) started on MTX at the highest tolerated dose 
within 6 months of diagnosis. Ninety patients (49%) continued MTX monotherapy at 
1 year. Of these patients, 44 (49%) achieved minimal disease activity (MDA) by 6 
months, and only 33 maintained MDA status at 1 year. MTX monotherapy was 
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concluded to be insufficient therapy for early PsA. While folate and vitamin B12 
levels were similar at baseline, differences between responders and non-responders 
included significantly higher baseline levels of IL-23, TNFα, interferon gamma, 
granulocyte-macrophage colony stimulating factor, and IL-10. Further, levels of IL-23 
and IL-10 evolved differently on MTX monotherapy in responders versus 
non-responders. Further work is ongoing to characterize the patients. 
Dr. Philip Helliwell presented Graham Chapman’s project on behalf of the 
EffeCt of Psoriatic Arthritis on Plantar shEar Stress (ESCAPES) study group. 
This ongoing study aims to examine the hypothesis that abnormal shear stresses in 
the foot are a contributory factor in the development of dactylitis of the toes in PsA. 
As part of this project, a new custom-made shear stress device was manufactured 
and is now ready for laboratory in vivo measurements. The project is planned to be 
completed by summer 2020. 
MRI 
Drs. Walter Maksymowych and Mikkel Østergaard presented an update on the 
ongoing work with whole-body MRI methodology for the objective assessment of 
inflammation in synovium, tendon, and bone, together with large joint-scoring 
methodologies for the assessment of inflammation in the hip and knee.  
A preliminary scoring method has been developed for whole-body MRI that 
assesses synovitis and osteitis in 83 peripheral joints and 33 entheses (0-3 grading 
scheme per joint or enthesis) with good reliability attained in a preliminary exercise of 
8 patients. The sensitivity to change and discriminatory ability between 
spondyloarthritis (SpA) patients treated with TNF-inhibitors and placebo have been 
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demonstrated. This method is expected to be particularly relevant in patients with 
PsA.  
The Hip MRI Inflammation Scoring System (HIMRISS), a granular method for 
scoring bone marrow lesions in the hip, has been developed and is based on the use 
of software that applies an overlay to segment the femoral head and acetabulum. 
This allows multiple regions to be scored directly on a web-based interface of 
consecutive MRI slices through the joint (scoring range 0-100), dispensing entirely 
with the use of scoring spreadsheets. Excellent reliability has been documented in 
patients with osteoarthritis (OA) of the hip for detection of lesions at a cross-sectional 
level, and very good reliability has been documented in detecting change 8 weeks 
after intra-articular glucocorticoid injection in MRIs from 90 patients assessed by 8 
readers. 
The system is now ready for testing in PsA (e.g., assessing the discrimination 
between treatment groups in clinical trials). Segmentation based on hip joint 
effusion/synovitis is also performed. A quantitative assessment method, which is 
hoped to be superior to semi-quantitative assessment, is being developed. Work on 
automation and comparisons with ultrasound for measuring effusion are also being 
performed. For the knee, a similar quantitative method, the Knee MRI Inflammation 
Scoring System (KIMRISS), has been compared with the MRI OA Knee Score 
(MOAKS) scoring system in patients with knee OA and has been shown to have 
excellent reliability and better reproducibility. 
 Further, the group has been working on a literature review on the utility of 
MRI in enthesitis. Lastly, an enthesitis assessment system, including exact 
definitions of the various pathologies involved, has been developed and validated, 
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with good reproducibility and sensitivity to change. The next steps are to apply the 
MRI techniques in clinical trials and PsA patient cohorts as well as to further develop 
and validate the methods on a modular plane. 
PRPs 
The 2019 annual GRAPPA meeting was the seventh at which PRPs have been 
present. There were 11 PRPs who attended (including 2 new members) from North 
America, South America, Europe, and Asia. The PRP pre-meeting included 
presentations on precision medicine and composite endpoints. PRPs were active 
participants in the meeting’s individual and breakout sessions. Individual PRPs also 
presented during the MTX panel debate. The PRPs continue to be active in several 
ongoing GRAPPA activities including the CRN, GRAPPA-OMERACT working group 
and subgroups, Best Practices, and education.  
From a governance perspective, the PRPs reported that the PRP Handbook 
was completed, approved by the GRAPPA Executive Committee, and adopted. 
Along with the PRP Policies and Procedures, these 2 documents not only define how 
the PRP group functions and is governed but also support increased group 
effectiveness. Reflecting the governance, the PRP network has now been able to 
fully implement the Chair, Chair-elect, and Immediate Past Chair model, with each 
position held for 2 years.  
Education Committee 
As a core objective of GRAPPA’s mission, GRAPPA members around the world 
provide psoriatic disease education to many people, including other health care 
professionals, patients and their families, and stakeholders. On behalf of the 
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Education Committee, Dr. Philip Mease discussed a variety of educational activities, 
including educational symposia, the slide library, and educational videos. He also 
discussed newer efforts that are aimed at virtual opportunities, such as 
videoconferencing and podcasts, to reach broader non-rheumatology/dermatology 
audiences.  
In the last decade, many events that have occurred around the world have 
included accredited continuing medical education (CME) and non-CME symposia. 
The predominantly US-based CME initiatives have been the GRAPPA-SpA 
Research and Treatment Network (SPARTAN) PsA-SpA symposia, offered as 2-
hour, half-day, and full-day symposia, and the GRAPPA Rheum-Derm PsA-psoriasis 
symposia. Educational symposia are also conducted around the globe with industry 
support. Symposia in India have partnered up to 3 international GRAPPA faculty with 
up to 3 regional faculty and include an ultrasound component. Other events that 
have occurred or are planned for 2019-2020 include (1) a symposium in Taiwan 
(November 2019); (2) symposia in Mumbai (November 2019 and February 2020); (3) 
a symposium in Dubai (September 2019); (4) events at the Asia Pacific League of 
Associations for Rheumatology (APLAR) meeting (symposium and GRAPPA 
meeting [April 2019, Brisbane, Australia; and April 2020, Kyoto, Japan]); (5) events 
at the Pan American League of Associations for Rheumatology (PANLAR) meeting 
(symposium and GRAPPA meeting [April 2019, Quito, Ecuador; and April 2020, 
Miami, Florida, USA]); and (6) events at the African League of Associations for 
Rheumatology (AFLAR) meeting (September 2019, Mauritius). 
Guidelines were also provided to qualify an educational symposium as 
GRAPPA-approved. GRAPPA member involvement is required in planning the 
symposium agenda. GRAPPA staff could assist with the administrative footwork 
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(e.g., grant applications, identifying audiences, travel logistics, and supporting 
document creation). GRAPPA faculty tasks include content creation and updates, as 
well as presentation. Further, participating faculty will have the opportunity to receive 
mentoring to improve cultural sensitivity during presentations.  
GRAPPA aims to provide education in less-resourced areas of the world and 
is exploring the provision of virtual educational opportunities with videoconferencing 
and podcasts. Other educational endeavours include the GRAPPA slide set, which is 
available for use by members. The popular GRAPPA smartphone application (app) 
launched in 2018 and is available in 14 languages. Work is ongoing to obtain grant 
funding to cover the addition of new languages. The website also continues to host 
educational content with a plan to provide the GRAPPA videos for members to use 
for educational and noncertification purposes in the next year. 
OMERACT-GRAPPA Outcome Measure Project 
After updating the core domain set for PsA in 2016, the GRAPPA-OMERACT 
Outcome Measure Working Group has continued its work to develop the core 
outcome measurement set. The presenters (Drs. Ying Ying Leung, Ana-Maria Orbai, 
William Tillett, and Dafna Gladman) reminded attendees that at OMERACT 2018, 
the 66/68 swollen and tender joint count was endorsed to measure musculoskeletal 
(MSK) disease activity-peripheral arthritis, and the PsA Impact of Disease 12-item 
questionnaire (PsAID12) was provisionally endorsed to evaluate health-related 
quality of life. The working group subsequently prioritized the determination of core 
measures for 4 additional domains: MSK disease activity-enthesitis, physical 
function, fatigue, and structural damage. Workstreams for each domain are led by a 
GRAPPA-OMERACT steering committee member and include at least 2 PRPs. 
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Identified instruments that assess each domain will be appraised using the 
OMERACT Filter 2.1, a set of standards by which to evaluate each instrument for 
truth, discrimination, and feasibility. Instruments will be proposed for the core 
outcome measurement set based on the available evidence and will be presented for 
endorsement by OMERACT. A new endorsement process from OMERACT is 
planned that will allow approvals through a web-based portal in real time rather than 
through the biennial face-to-face OMERACT congress. 
Axial Project 
Drs. Dafna Gladman and Denis Poddubnyy presented the ongoing Assessment of 
SpA international Society (ASAS)-GRAPPA axial project, which aims to develop a 
consensus definition of axial involvement in PsA. From December 2018 through 
January 2019, a web-based survey was conducted among ASAS and GRAPPA 
members that aimed to identify the parameters relevant to the definition of axial 
involvement in PsA using an established decision-making algorithm (Potentially All 
Pairwise RanKings of all possible Alternatives [PAPRIKA] method with practical 
implementation through the 1000minds web application). The survey was completed 
by 186 ASAS and GRAPPA members (106 ASAS members and 123 GRAPPA 
members, with 43 members belonging to both societies). 
According to the survey results, the following 4 parameters that reflect 
objective signs of inflammatory involvement of the axial skeleton received the 
highest ranking: (1) presence of structural damage on a radiograph (X-ray) of the 
sacroiliac joints (radiographic sacroiliitis of at least grade II bilaterally or grade III 
unilaterally); (2) presence of structural damage on an X-ray of the spine; (3) 
presence of subchondral bone marrow edema/osteitis on an MRI of the sacroiliac 
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joints compatible with SpA; and (4) presence of bone marrow edema/osteitis on MRI 
of the spine compatible with SpA. These parameters represented the most likely 
candidates for the future consensus definition. Currently, a prospective study is 
planned in PsA with comprehensive imaging of the axial skeleton to generate data to 
validate the expected definition.  
Ultrasound Enthesitis Project 
Dr. Lihi Eder presented an update on the GRAPPA Diagnostic Ultrasound Enthesitis 
Tool (DUET) project. The objective of this GRAPPA initiative is to develop a 
sonographic tool to enable the early diagnosis of PsA, especially as sonography is 
more sensitive and specific than clinical examination in detecting enthesitis. From 
pilot studies, a candidate set of entheses was selected. Utilizing these entheses, a 
larger study is planned within the GRAPPA membership to ensure a diverse 
population is evaluated to test this potential diagnostic tool. The protocol has been 
reviewed by the steering committee, and training materials (videos, acquisition atlas) 
are being developed. A post-meeting workshop was held to understand potential 
barriers to study conduct in various countries. The possibility of performing local 
reading in addition to the planned central reading was also explored. Members from 
Europe, Israel, India, as well as North America were present. Challenges within each 
system were discussed, as well as potential solutions. Timelines to seek study 
funding were clarified, with the planned study start in mid-2020. 
Early Psoriatic Disease Systematic Literature Review 
Dr. Gabriele De Marco reported on the set up of a systematic literature review 
project entitled "Non-topical pharmacological treatment of early, untreated (disease 
modifying antirheumatic drug [DMARD]-naïve, systemic therapy-naïve) psoriatic 
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disease: a systematic review." Most trials have been limited with a focus on severe 
disease of the skin or joints, without looking at more comprehensive indices in 
outcomes assessment. The target condition was defined so that clinical studies 
investigating (1) MSK and/or cutaneous manifestations; or (2) untreated psoriatic 
disease in its early stage could be included. Case reports or studies assessing the 
effects of topical therapies were excluded. The range of outcome measures 
considered was broad in order to assess across the spectrum of disease 
manifestations and to maximize the sensitivity of the search strategy. The resources 
accessed to find the available evidence covered a time range from 1946 to May 
2019 and spanned across electronic databases, trial registers, and conferences 
proceedings. The flow diagram presented during the talk highlighted the substantial 
number of records (144,299) that were identified through electronic database 
searches. The diagram also provided the status of the ongoing selection activities 
performed by the team and the timeline for publication. 
Conclusion 
This paper summarizes GRAPPA’s recent work on several projects. These projects 
are part of GRAPPA’s ongoing mission to address educational and unmet research 
needs for psoriatic disease, to create opportunities for networking within the psoriatic 
community, and to optimize patient care through collaborative care networks and 
treatment recommendations.  
